Navigation Links
Experimental Drug Fights Bone Marrow Cancers
Date:12/9/2008

There are currently no FDA-approved treatments for these malignancies

TUESDAY, Dec. 9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), according to U.S. researchers who conducted tests in mice and human cells.

The findings were to be presented Tuesday at the annual meeting of the American Society of Hematology, in San Francisco.

The researchers, from Oregon Health & Science University's Knight Cancer Institute, found that CYT387 was "very effective" against a specific type of cancer cell driven by an enzyme mutation called JAK2-V617F. The drug binds to the V617F mutation in the JAK2 enzyme.

"In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very promising compound," researcher Dr. Thomas Bumm said in a university news release.

There are no U.S. Food and Drug Administration-approved targeted treatments for the "big three" MPDs -- polycythemia vera, essential thrombocythemia and primary myelofibrosis.

"Based on the efficacy we demonstrated in the mouse model, there is a good chance that CYT387 will enter clinical trials as early as 2009," principal investigator Dr. Michael Deininger, head of the hematological malignancies program, said in the news release.

The study was funded by Cytopia Research Pty Ltd. of Australia, which makes the drug.

More information

The Leukemia and Lymphoma Society has more about MPDs.



-- Robert Preidt



SOURCE: Oregon Health & Science University, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Experimental Vaginal Gel Doesnt Ward Off HIV
2. Experimental TB drug explodes bacteria from the inside out
3. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
4. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
5. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
6. Experimental Drug Fights Multiple Sclerosis Activity
7. Experimental Therapy Beats Back One Patients Melanoma
8. Experimental agent blocks prostate cancer in animal study
9. Experimental Drug Eases Symptoms of Mild Alzheimers
10. Experimental Blood Substitutes Unsafe, Study Finds
11. Honda to Showcase Experimental Walking Assist Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fights Bone Marrow Cancers
(Date:3/22/2017)... Valhalla, New York (PRWEB) , ... March 22, ... ... Blythedale Children’s Hospital have entered into a research collaboration to translate advances in ... with neurological impairments at Blythedale and beyond. The collaboration seeks to improve movement, vision, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo Agency, a ... the New York metropolitan region, is embarking on a cooperative charity drive with ... At present, more than two and a half million children in the United ...
(Date:3/22/2017)... TX (PRWEB) , ... March 22, 2017 , ... ... insurance consultation, financial planning, and related services to communities across eastern Texas, is ... the goal of providing meals to hungry children and adults. , Consistently ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Zabbia Insurance Agency, ... families and business owners in the greater Nassau County area, is embarking on ... , Every 3 minutes, someone in America is diagnosed with blood cancer. Every ...
(Date:3/22/2017)... ... March 22, 2017 , ... College basketball surges to its peak during the ... – that is, recruiting people to be foster parents. Through a televised spot, Coach ... in foster care due to abuse, neglect and other family challenges. People who respond ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017 A new independent study ... the proven ultraviolet-C (UV-C) disinfection solution of choice ... Published in the March issue ... , the peer-reviewed study of UV-C disinfection systems ... General Hospital and Rochester General Hospital. According to ...
(Date:3/22/2017)... , March 22, 2017 ... market is growing rapidly due to the significant development ... published by Allied Market Research, the global electrophysiology market ... to reach $8.271 billion by 2022, with a GAGR ... is used to diagnose abnormal heartbeats or arrhythmia. The ...
(Date:3/22/2017)... 22, 2017 Kalorama Information has noted five ... those following the industry.  This month the FDA granted a ... the POC testing market has reached $18.4 billion in ... facing a legal battle and the acquisition by Abbott ... launched a new chemistry analyzer and researchers evaluated fetal ...
Breaking Medicine Technology: